HC Wainwright & Co. Reiterates Buy on Insmed, Announces $220 Price Target
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Andrew S. Fein reiterates Insmed (NASDAQ:INSM) with a Buy and announces $220 price target.
HC Wainwright & Co. analyst Andrew S. Fein reiterates Insmed (NASDAQ:INSM) with a Buy and announces $220 price target.